Search Results
The product title you are looking for is no longer available. Other similar products that may interest you are listed below:
| Title | Publication Date | Price | Relevance |
|---|---|---|---|
| Stakeholder Opinions: Endometriosis Scientific Clarity Will Unlock Market Potential |
Dec 2007 | £2,400 | 100% |
| Stakeholder Opinion: Erectile Dysfunction Identifying product differentiation and patient segmentation strategies |
Dec 2006 | £2,400 | 99% |
| Stakeholder Opinions: Hormonal Contraceptives New directions in a competitive market |
Nov 2006 | £2,400 | 96% |
| Pharma and Social Media - the leaders and followers | Aug 2009 | £175 | 94% |
| Stakeholder Opinions: Bone Metastases Impending Patent Expiries May Help Make or Break Newer Agents |
Mar 2008 | £2,400 | 94% |
| Stakeholder Opinion: Atopic Dermatitis A high level of unmet need creates market opportunities |
Mar 2007 | £2,400 | 93% |
| Stakeholder Opinions: Spinal Cord Injury Attractive niche market with multi-billion dollar potential |
Mar 2010 | £2,405 | 92% |
| Stakeholder Opinions: Sexually Transmitted Diseases An underestimated threat lacking interventions to prevent transmission |
Aug 2010 | £2,405 | 91% |
| Stakeholder Opinions: Gynecological Cancers Niche opportunities in advanced disease |
Dec 2006 | £2,400 | 91% |
| Stakeholder Opinions: Vaccine antigen delivery technologies Molecular systems to open new markets |
May 2009 | £2,405 | 91% |
| Stakeholder Opinions: Sarcomas | Dec 2008 | £2,405 | 90% |
| Stakeholder Opinions: Parkinson\'s Disease Review of Key Commercial Opportunities in the Symptomatic Treatment Market |
Jul 2006 | £1,335 | 89% |
| Stakeholder Opinions: Bladder Cancer New drugs needed to challenge ineffective 20year old drugs | Nov 2008 | £2,405 | 89% |
| Psoriasis Market Forecast | Dec 2010 | £9,615 | 89% |
| Pharmaceutical Brand PR Developing Engaging Campaigns and Measuring ROI |
Sep 2011 | £355 | 88% |
| Stakeholder Opinions: Respiratory viral infections Respiratory syncytial virus, parainfluenza virus and human metapneumovirus as promising new targets |
Apr 2010 | £2,405 | 87% |
| Stress Urinary Incontinence Opinion Divided on Drug Therapy |
Apr 2006 | £5,495 | 86% |
| Stakeholder Opinions: Hepatocellular cancer | Dec 2010 | £2,405 | 85% |
| Stakeholder Opinions: Alpha 1 Antitrypsin Deficiency | Dec 2007 | £2,400 | 84% |
| Oncology Market Leaders Analyses and Outlook – 2010-2025 |
Jan 2010 | £1,499 | 84% |
| Stakeholder Opinions: Biomarkers in Rheumatology Awaiting the next step towards personalized medicine |
Dec 2009 | £2,405 | 84% |
| Hot Topics in Type 2 Diabetes: Complications and Comorbidities Physician insight on diabetic complications, comorbidities and treatment |
Aug 2011 | £3,605 | 83% |
| Stakeholder Opinions: Respiratory Syncytial Virus (RSV) A market yet to reach its full potential |
Dec 2006 | £2,400 | 83% |
| Stakeholder Opinions Respiratory Syncytial Virus (RSV) A market yet to reach its full potential |
Jan 2007 | £1,265 | 83% |
| Stakeholder Opinions: Irritable Bowel Syndrome Potentially profitable market is open for the taking |
Jun 2007 | £2,405 | 82% |
| Stakeholder Opinions: Ovarian Cancer Approaching the era of molecular targeted therapy |
Jul 2010 | £2,405 | 82% |
| Stakeholder Opinions: Sexual Dysfunction The quest for the new Viagra continues |
Mar 2010 | £4,805 | 82% |
| Dry Overactive Bladder A Precursor to 'Wet Overactive Bladder'? |
Apr 2006 | £1,370 | 82% |
| The Royalty Rate Report 2011 A Comprehensive Assessment of Valuation in the Pharmaceutical Sector |
Jun 2011 | £4,950 | 81% |
| Stakeholder Opinions: Therapeutic Vaccines A far-off promise of greatness |
Dec 2009 | £2,405 | 81% |
